株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Immune Response BioPharma, Inc. の製品パイプライン分析

Immune Response BioPharma Inc - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 319979
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
Immune Response BioPharma, Inc. の製品パイプライン分析 Immune Response BioPharma Inc - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 42 Pages
概要

Immune Response BioPharma, Inc. は米国に本社をもつ製薬企業で、自己免疫疾患や感染症を対象としたワクチンを開発しています。同社の製品は多発性硬化症、肺血性ショック、HIV/AIDS、リウマチ性関節炎、クローン病、乾癬などの他、痛風や糖尿病、心臓疾患などの治療に使われています。

当レポートでは、Immune Response BioPharma, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Immune Response BioPharma, Inc. の基本情報

  • Immune Response BioPharma, Inc. の概要
  • 主要情報
  • 企業情報

Immune Response BioPharma, Inc. :R&Dの概要

  • 主な治療範囲

Immune Response BioPharma, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Immune Response BioPharma, Inc. :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Immune Response BioPharma, Inc. :薬剤プロファイル

  • IR-103
  • IR-501
  • IR-703
  • IR-502
  • IR-902
  • RemuneX
  • IR-007
  • IR-1000
  • IR-1002
  • IR-2020
  • IR-222
  • IR-444
  • IR-555
  • IR-777
  • IR-888
  • IR-999

Immune Response BioPharma, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別

Immune Response BioPharma, Inc. :最近のパイプライン情報

Immune Response BioPharma, Inc. :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08177CDB

Summary

Global Markets Direct's, 'Immune Response BioPharma Inc - Product Pipeline Review - 2016', provides an overview of the Immune Response BioPharma Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immune Response BioPharma Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Immune Response BioPharma Inc
  • The report provides overview of Immune Response BioPharma Inc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Immune Response BioPharma Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Immune Response BioPharma Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Immune Response BioPharma Inc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Immune Response BioPharma Inc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Immune Response BioPharma Inc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Immune Response BioPharma Inc Snapshot
    • Immune Response BioPharma Inc Overview
    • Key Facts
  • Immune Response BioPharma Inc - Research and Development Overview
    • Key Therapeutic Areas
  • Immune Response BioPharma Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Immune Response BioPharma Inc - Pipeline Products Glance
    • Immune Response BioPharma Inc - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • Immune Response BioPharma Inc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immune Response BioPharma Inc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Immune Response BioPharma Inc - Drug Profiles
    • IR-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-2020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-444 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-555 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-999 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IRE-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IRR-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IRS-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Remune - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Immune Response BioPharma Inc - Pipeline Analysis
    • Immune Response BioPharma Inc - Pipeline Products by Target
    • Immune Response BioPharma Inc - Pipeline Products by Route of Administration
    • Immune Response BioPharma Inc - Pipeline Products by Molecule Type
  • Immune Response BioPharma Inc - Dormant Projects
  • Immune Response BioPharma Inc - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immune Response BioPharma Inc, Key Facts
  • Immune Response BioPharma Inc - Pipeline by Indication, 2016
  • Immune Response BioPharma Inc - Pipeline by Stage of Development, 2016
  • Immune Response BioPharma Inc - Monotherapy Products in Pipeline, 2016
  • Immune Response BioPharma Inc - Pre-Registration, 2016
  • Immune Response BioPharma Inc - Phase II, 2016
  • Immune Response BioPharma Inc - Phase I, 2016
  • Immune Response BioPharma Inc - Preclinical, 2016
  • Immune Response BioPharma Inc - Pipeline by Target, 2016
  • Immune Response BioPharma Inc - Pipeline by Route of Administration, 2016
  • Immune Response BioPharma Inc - Pipeline by Molecule Type, 2016
  • Immune Response BioPharma Inc - Dormant Developmental Projects,2016

List of Figures

  • Immune Response BioPharma Inc - Pipeline by Top 10 Indication, 2016
  • Immune Response BioPharma Inc - Pipeline by Stage of Development, 2016
  • Immune Response BioPharma Inc - Monotherapy Products in Pipeline, 2016
  • Immune Response BioPharma Inc - Pipeline by Route of Administration, 2016
  • Immune Response BioPharma Inc - Pipeline by Molecule Type, 2016
Back to Top